PROPANAMIDE, N-(4-(2,2-DIMETHYL-1-OXOPROPYL)-5-((((2-(ETHYLAMINO)ETHYL)SULFONYL)AMINO)METHYL)-4,5-DIHYDRO-5-PHENYL-1,3,4-THIADIAZOL-2-YL)-2,2-DIMETHYL-, (5R)-
Acute Leukemia
Eli Lilly and CompanySmall moleculePhase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 73/ 100
Competitive context
60 Active assets in the Acute Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Sawa Ito, MD | Phase 2/3 | BB |
Cyclophosphamide Sawa Ito, MD | Phase 4 | BB |
Cytosin-Arabinosid Janssen Research & Development, LLC | Phase 2/3 | BB |
ETOPOSIDE Nanfang Hospital, Southern Medical University | Phase 2/3 | BB |
METHOTREXATE SWOG Cancer Research Network | Phase 3 | BB |
View all 50 →
Same molecule, other indications
PROPANAMIDE, N-(4-(2,2-DIMETHYL-1-OXOPROPYL)-5-((((2-(ETHYLAMINO)ETHYL)SULFONYL)AMINO)METHYL)-4,5-DIHYDRO-5-PHENYL-1,3,4-THIADIAZOL-2-YL)-2,2-DIMETHYL-, (5R)- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →